Showing results (1181-1190 of 3,535) with videos related to

Sort By:
Pageof 354
Biological & Pharmaceutical Bulletin|December 16, 1998
Vasoactive effects of cimicifugic acids C and D, and fukinolic acid in cimicifuga rhizomeM Noguchi, M Nagai, M Koeda, et al.
American Journal of Respiratory and Critical Care Medicine|August 1, 1995
Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitisH Mukae, J Kadota, S Kohno, et al.
The Thoracic and Cardiovascular Surgeon|October 1, 1995
A new approach for bronchoplastic procedures in the treatment of bronchial carcinoid tumorsK Kawahara, T Shiraishi, K Okabayashi, et al.
Analytical Chemistry|March 17, 2004
A strategy for identifying differences in large series of metabolomic samples analyzed by GC/MSPär Jonsson, Jonas Gullberg, Anders Nordström, et al.
Journal of Bone and Mineral Metabolism|December 24, 2004
Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG)Nobuhiro Sasaki, Eiji Kusano, Hideaki Takahashi, et al.
Kansenshogaku Zasshi. the Journal of the Japanese Association for Infectious Diseases|October 1, 1993
[An animal model of Pneumocystis carinii pneumonia and therapeutic efficacy of interferon-gamma in this model]A Nakamoto, K Kitsukawa, T Ishimine, et al.
Journal of Gastroenterology|April 1, 1994
A resected case of giant leiomyosarcoma of the pancreasT Sato, Y Asanuma, H Nanjo, et al.
The Annals of Thoracic Surgery|January 1, 1991
Rupture of a benign mediastinal teratoma into the right pleural cavityT Hiraiwa, T Hayashi, M Kaneda, et al.
Journal of Arrhythmia|August 3, 2017
Study design of GENERAL (general practitioners and embolism prevention in NVAF patients treated with rivaroxaban: Real-life evidence): A multicenter prospective cohort study in primary care physicians to investigate the effectiveness and safety of rivaroxaban in Japanese patients with NVAFKengo Kusano, Masaharu Akao, Hikari Tsuji, et al.
Molecular and Clinical Oncology|August 8, 2017
Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinomaNobuki Furubayashi, Takahito Negishi, Takuya Yamashita, et al.
Pageof 354